Oncology News | pharmaphorum

News

Long-term third-party manufacturing contracts and a slower-than-expected rollout of its cancer ADCs have driven Daiichi Sankyo into a net loss.

News

CellCentric has raised $220 million in a Series D financing that will help fund pivotal trials of p300/CBP inhibitor inobrodib in multiple myeloma.

News

BioNTech's plan to shed 22% of its workforce and stop COVID-19 vaccine production has earned it a rebuke from Germany's third-largest labour union.

News

Cytospire was in the spotlight this morning after announcing an oversubscribed Series A to fund a new form of T-cell engager (TCE) for cancer.

News

For the first time in its 16-year history, Deloitte's annual report on pharma R&D returns sees obesity replace cancer as the largest driver.

News

Arvinas and Pfizer's Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.